Journal Mobile Options
Table of Contents
Vol. 21, No. 1, 2006
Issue release date: December 2005
Dement Geriatr Cogn Disord 2006;21:1–8

Olanzapine versus Haloperidol in the Treatment of Agitation in Elderly Patients with Dementia: Results of a Randomized Controlled Double-Blind Trial

Verhey F.R.J. · Verkaaik M. · Lousberg R.
aDepartment of Psychiatry and Neuropsychology, University of Maastricht, Maastricht, and bPrins Claus Center for Mental Health, Sittard, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The goal of this study was to compare the efficacy and safety of olanzapine versus haloperidol in the treatment of agitation and aggression in patients with dementia. The subjects were 58 out-patients with dementia and agitation. After baseline assessments and, if necessary, a period of wash-out of a previous antipsychotic drug, they were randomly assigned to 5 weeks of double-blind treatment with either olanzapine or haloperidol. The first 2 weeks were used for dose titration. Subsequently, the patients received a fixed dose of either olanzapine (average dose 4.71 mg) or haloperidol (average dose 1.75 mg) from day 14 to day 35. Both olanzapine and haloperidol decreased agitation significantly (decrease in Cohen-Mansfield Agitation Inventory scores), but there was no significant difference between the two drugs. The two drugs had comparable effects on all secondary outcome measures. They were well tolerated and had a similar side-effect pattern. Our study could not demonstrate the superiority of olanzapine, compared to haloperidol, for the treatment of agitation in patients with dementia.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Aalten P, de Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, et al: Behavioral problems in dementia: a factor analysis of the Neuropsychiatric Inventory. Dement Geriatr Cogn Disord 2003;15:99–105.
  2. Teri L, Borson, S, Kiyak A, Yamagishi M: Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimer’s disease. JAGS 1989;37:109–116.
  3. Walsh JS, Welch HG, Larson EB: Survival of outpatients with Alzheimer type dementia. Ann Intern Med 1990;113:429–434.
  4. Alexopoulos GS, Kahn D, Frances AJ, Carpenter D: Treatment of Agitation in Older Persons with Dementia. New York, McGraw-Hill, 1998.
  5. De Deyn P, Rabheru K, Rasmussen A, Bocksberger J, Dautzenberg P, Eriksson S, et al: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946–955.
  6. Devanand DP, Marder K, Michaels KS, Sackheim HA, Bell K, Sullivan MA, et al: A randomized placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviours in Alzheimer’s disease. Am J Psychiatry 1998;155:1512–1520.
  7. Allain H, Dautzenberg PHJ, Maurer K, Schuck S, Bonhomme D, Gerard D: Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology 2000;148:361–366.
  8. Auchus AP, Bissey-Black C: Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997;9:591–593.
  9. Teri L, Logsdon RG, Peskind ER, Raskind M, Weiner MF, Tractenberg RE, et al: Treatment of agitation in AD – A randomized placebo-controlled clinical trial. Neurology 2000;55:1271–1278.
  10. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA: Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75.
  11. Committee on Safety of Medicines: Atypical antipsychotic drugs and stroke. 2004, available from:
  12. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156–1162.
  13. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 1986;34:711–721.
  14. De Jonghe JF, Kat MG: Factor structure and validity of the Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D). J Am Geriatr Soc 1996;44:888–889.
  15. Cummings JL, Mega M, Gray K, Rosenbergh-Thompson S, Carusi DA, Gornbein J: The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  16. Kat MG, de Jonghe JF, Aalten P, Kalisvaart CJ, Droes RM, Verhey FR: Neuropsychiatric symptoms of dementia: psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI). Tijdschr Gerontol Geriatr 2002;33:150–155.
  17. Folstein M, Folstein S, McHugh P: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1977;12:189–198.
  18. Lingjaerde O, Ahlfors UG, Bech P, et al: The UKU side-effects rating scale. Acta Psychiatr Scand 1987;76(suppl):1–100.

    External Resources

  19. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11–19.
  20. Cohen-Mansfield J: Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986;34:722–727.
  21. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(suppl 6):s10–s16.
  22. Aalten P, Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, et al: Behavioral problems in dementia: a factor analysis of the Neuropsychiatric Inventory (NPI). Dement Geriatr Cogn Disord 2003;15:99–105.
  23. Guy WE (ed): Abnormal Involuntary Movement Scale (AIMS); in: ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol and Drug Abuse and Mental Health Administration, NIHM Psychopharmacology Research Branch, Rockville, 1976, pp 218–222.
  24. Bol Y, Verhey FRJ, Verkaaik AJB, Peters ML, Hooymans PM: Olanzapine versus Haloperidol in the Treatment of Behavioural Agitation in Elderly Patients with Dementia: Preliminary Findings of a Pilot Study. Maastricht, University of Maastricht, 1998.
  25. US Food and Drug Administration: FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005, available from:
  26. Street J, Clark WS, Gannon KS, Mitan S, Kadam D, Tamura R, et al: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s disease in nursing care facilities: a double blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968–976.
  27. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107–115.
  28. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004;19:115–126.
  29. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al: Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ 2005;330:874.
  30. Mowat D, Fowlie D, MacEwan T: CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 2004;328:1262.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50